GAMMA Investing LLC boosted its holdings in Krystal Biotech, Inc. (NASDAQ:KRYS - Free Report) by 50,249.4% in the first quarter, according to its most recent filing with the SEC. The institutional investor owned 121,342 shares of the company's stock after buying an additional 121,101 shares during the period. GAMMA Investing LLC owned 0.42% of Krystal Biotech worth $21,878,000 as of its most recent SEC filing.
Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Blue Trust Inc. boosted its stake in Krystal Biotech by 74.4% during the fourth quarter. Blue Trust Inc. now owns 1,015 shares of the company's stock valued at $159,000 after buying an additional 433 shares during the last quarter. KBC Group NV lifted its position in shares of Krystal Biotech by 46.3% during the fourth quarter. KBC Group NV now owns 939 shares of the company's stock worth $147,000 after purchasing an additional 297 shares during the last quarter. abrdn plc grew its stake in Krystal Biotech by 32.5% in the 4th quarter. abrdn plc now owns 57,033 shares of the company's stock worth $8,935,000 after acquiring an additional 13,979 shares in the last quarter. Entropy Technologies LP bought a new position in Krystal Biotech in the fourth quarter worth approximately $548,000. Finally, Certuity LLC bought a new stake in shares of Krystal Biotech in the fourth quarter valued at about $214,000. Institutional investors own 86.29% of the company's stock.
Wall Street Analysts Forecast Growth
A number of research analysts have recently issued reports on KRYS shares. HC Wainwright reiterated a "buy" rating and issued a $240.00 price target on shares of Krystal Biotech in a report on Tuesday, May 6th. Citigroup cut their target price on Krystal Biotech from $215.00 to $155.00 and set a "neutral" rating on the stock in a research report on Friday, May 16th. Chardan Capital restated a "buy" rating and set a $219.00 price objective on shares of Krystal Biotech in a research note on Wednesday, May 7th. Jefferies Financial Group started coverage on Krystal Biotech in a report on Wednesday, March 5th. They issued a "buy" rating and a $245.00 price objective for the company. Finally, Guggenheim dropped their price target on shares of Krystal Biotech from $195.00 to $189.00 and set a "buy" rating on the stock in a research report on Wednesday, May 7th. One equities research analyst has rated the stock with a hold rating, seven have assigned a buy rating and one has issued a strong buy rating to the company's stock. Based on data from MarketBeat.com, the company currently has an average rating of "Buy" and an average target price of $211.13.
Check Out Our Latest Research Report on KRYS
Krystal Biotech Stock Down 0.6%
Shares of NASDAQ KRYS traded down $0.86 during midday trading on Monday, hitting $136.08. The stock had a trading volume of 342,345 shares, compared to its average volume of 312,163. Krystal Biotech, Inc. has a 1 year low of $122.80 and a 1 year high of $219.34. The stock has a 50 day simple moving average of $149.85 and a 200-day simple moving average of $162.99. The company has a market capitalization of $3.93 billion, a PE ratio of 45.51 and a beta of 0.65.
Krystal Biotech (NASDAQ:KRYS - Get Free Report) last posted its quarterly earnings results on Tuesday, May 6th. The company reported $1.20 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $1.38 by ($0.18). Krystal Biotech had a net margin of 30.69% and a return on equity of 11.41%. The company had revenue of $88.18 million during the quarter, compared to analysts' expectations of $98.66 million. As a group, analysts expect that Krystal Biotech, Inc. will post 6.14 earnings per share for the current fiscal year.
Insider Buying and Selling at Krystal Biotech
In other Krystal Biotech news, insider Suma Krishnan sold 25,000 shares of the company's stock in a transaction dated Thursday, March 13th. The shares were sold at an average price of $177.79, for a total value of $4,444,750.00. Following the transaction, the insider now owns 1,463,711 shares of the company's stock, valued at $260,233,178.69. This represents a 1.68% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through this link. 13.70% of the stock is currently owned by company insiders.
About Krystal Biotech
(
Free Report)
Krystal Biotech, Inc, a commercial-stage biotechnology company, discovers, develops, and commercializes genetic medicines for patients with rare diseases in the United States. It commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB).
Featured Stories
Before you consider Krystal Biotech, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Krystal Biotech wasn't on the list.
While Krystal Biotech currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
MarketBeat's analysts have just released their top five short plays for July 2025. Learn which stocks have the most short interest and how to trade them. Enter your email address to see which companies made the list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
